<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="999">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02035111</url>
  </required_header>
  <id_info>
    <org_study_id>Z-TSJN-JN-â…£</org_study_id>
    <nct_id>NCT02035111</nct_id>
  </id_info>
  <brief_title>A Randomized, Placebo-Controlled, Double-blind Study of Tianshu Capsule in the Treatment of Migraine.</brief_title>
  <official_title>To Evaluate the Safety and the Efficacy of Tianshu Capsule Treating Migraine in a Randomized, Placebo-Controlled, Double-blind, Multicenter Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Kanion Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Bionovo Medicine Development Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Kanion Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and the efficacy of Tianshu capsule
      treating Migraine Headache.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary headache disorders,particularly migraine is globally prevalent. Many studies show
      the burdens they impose: pain, disability, reduced quality of life (QoL), marked impairment
      of participation in work and social activities, and heavy financial costs.

      The purpose of this study is to evaluate the safety and the efficacy of Tianshu capsule
      treating Migraine Headache. To provide a safe and effective treatment of Migraine Headache.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in the frequency of attack of Migraine Per 4 weeks at Week 16 from baseline</measure>
    <time_frame>-4w,0,4w,8w,12w,16w</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in seizure duration of Migraine Per 4 weeks at Week 16 from baseline.</measure>
    <time_frame>-4w,0,4w,8w,12w,16w</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in degree of pain of Migraine Per 4 weeks at Week 16 from baseline.</measure>
    <time_frame>-4w,0,4w,8w,12w,16w</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the days using acute therapy of Migraine Per 4 weeks at Week 16 from baseline.</measure>
    <time_frame>-4w,0,4w,8w,12w,16w</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects whose number or days of migraine attacks reduce at least 50%.</measure>
    <time_frame>-4w,0,4w,8w,12w,16w</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of concomitant migrainous symptoms attacks Per 4 weeks at Week 16 from baseline.</measure>
    <time_frame>-4w,0,4w,8w,12w,16w</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments will be based on adverse event reports and the results of vital sign measurements, electrocardiogram, and clinical laboratory tests.</measure>
    <time_frame>0, 12w</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse event reports will be assessed at 0, 4w, 8w, 12w, 16w. clinical laboratory tests including WBC, RBC, HGB, PLT, LEU, ERY, PRO,Stool routine, ALT, AST, TBil, ALP, GGT, BUN, Cr will be assessed at 0, 12w.
Electrocardiogram will be assessed at 0, 12w. Vital sign measurements will be assessed at -4w, 0, 4w, 8w, 12w, 16w.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Tianshu capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four Tianshu capsules (0.34 g per capsule) by oral three times a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Four sugar pills (0.34 g per capsule) by oral three times a day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tianshu capsule</intervention_name>
    <arm_group_label>Tianshu capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must meet the Migraine diagnosis.

          -  Age of onset should be before age 50 years.

          -  Migraine must have been occurring for 1 year preceding entry into the trial.

          -  The number of migraine attack should be no less than 6 for a period of 3 months prior
             to Screening stage.

          -  The number of migraine days is to be 2-8 for a period of 1 month prior to screening
             for entry into the trial.

          -  Migraine days should be less than 15 for a period of 1 month prior to screening for
             entry into the trial.

          -  Ages 18-65.

          -  Participant can understand and complete the Headache diary.

          -  All participants signed the informed consent.

        Exclusion Criteria:

          -  Other migraine prophylactic medication is continued 3 months prior to the drug trial.

          -  Participants who have taken Tianshu capsule during 1 month prior to Screening stage.

          -  The number of acute treatment for migraine is more than 10 per month.

          -  Participants who have taken antipsychotics or antidepressant medications (unless only
             for migraine prophylaxis) during the previous 3 months.

          -  Participants who abuse alcohol or other drugs.

          -  Participants who are resistant to all acute migraine drugs prescribed optimally.

          -  hypotension or uncontrolled hypertension.

          -  Severe infections.

          -  Malignancy.

          -  Significant medical history of such as cardiac disease, cerebrovascular disease,
             liver disease, nephropathy etc.

          -  Known allergies or serious side effects with Tianshu capsule in the past.

          -  Breastfeeding, pregnant and potentially fertile women participant.

          -  History of cluster headaches, tension-type headache, vascular headache with
             non-migraine, drug - dependence headache.

          -  Secondary headaches, including hypertension, post-traumatic brain syndrome etc.

          -  Participants who have taken migraine prophylactic medication regularly during 1 month
             prior to Screening stage.

          -  Participants who are taking part in other clinical trials.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengyuan Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The People's Hospital,Huaibei</name>
      <address>
        <city>Huaibei</city>
        <state>Anhui</state>
        <zip>235000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Huang</last_name>
      <phone>86-18909610708</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SanMing First Hospital</name>
      <address>
        <city>Sanming</city>
        <state>Fujian</state>
        <zip>365000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaodong Wang</last_name>
      <phone>86-13559892998</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The People's Hospital,Cangzhou</name>
      <address>
        <city>Cangzhou</city>
        <state>Hebei</state>
        <zip>061000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanling Wang</last_name>
      <phone>86-13832761853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Langfang hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Langfang</city>
        <state>Hebei</state>
        <zip>065000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dequan Liu</last_name>
      <phone>86-18031603678</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The People's Hospital,Shijiazhuang</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiamin Li</last_name>
      <phone>86-13315995789</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The two six zero hospital of Chinese people's Liberation Army</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shujuan Tian</last_name>
      <phone>86-13333019039</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaifeng hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Kaifeng</city>
        <state>Henan</state>
        <zip>475000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinjun Ni</last_name>
      <phone>86-13839996100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luohe hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Luohe</city>
        <state>Henan</state>
        <zip>462000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baoshen Wang</last_name>
      <phone>86-13939563480</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan sixth hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cun Ouyang</last_name>
      <phone>86-13476222517</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yiyang central hospital</name>
      <address>
        <city>Yiyang</city>
        <state>Hunan</state>
        <zip>413000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Cao</last_name>
      <phone>86-13973740817</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin brain hospital</name>
      <address>
        <city>Siping</city>
        <state>Jilin</state>
        <zip>136000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Chen</last_name>
      <phone>86-18943407069</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinan hospital of traditional Chinese Medicine</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shike Zhao</last_name>
      <phone>86-13793137008</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The second affiliated hospital of Shandong Traditional Chinese Medicine University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huikui Zhuang</last_name>
      <phone>86-15269101189</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jining Medical University</name>
      <address>
        <city>Jining</city>
        <state>Shandong</state>
        <zip>272000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanlei Hao</last_name>
      <phone>86-18678766959</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jining First Hospital</name>
      <address>
        <city>Jining</city>
        <state>Shandong</state>
        <zip>272000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongrui Yan</last_name>
      <phone>86-15910000699</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shengyuan Yu</last_name>
      <phone>86-010-55499318</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daxing hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Beijing</city>
        <zip>102600</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenqing Ding</last_name>
      <phone>86-13261853981</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>January 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Tianshu capsule</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
